在包含环磷酰胺、阿霉素、长春新碱和泼尼松龙的化疗第一周期后，弥漫性大B细胞非霍奇金淋巴瘤患者中性粒细胞减少的频率和严重程度。

Frequency and severity of neutropenia in diffuse large B-cell non Hodgkin's lymphoma after first cycle of chemotherapy comprising cyclophosphamide, doxorubicin, vincristine with prednisolone.

作者信息

Nadeem Mohammad, Idrees Muhammad, Khattak Javeed, Hussain Iftikhar, Amin Zulfiqar, Arif Salman, Zeeshan Mansoor, Hussain Mussavir

机构信息

Department of Oncology, CMH, Rawalpindi, Pakistan.

出版信息

J Ayub Med Coll Abbottabad. 2011 Jan-Mar;23(1):80-3.

PMID:22830154

Abstract

BACKGROUND

Chemotherapy used for malignant diseases may produce severe neutropenia in first cycle which may compel for dose modification and early termination of therapy. This descriptive cross sectional study was planned to see the frequency and severity of neutropenia after first cycle of chemotherapy comprising cyclophosphamide, doxorubicin, vincristine with prednisolon in patients of diffuse large B-cell non Hodgkin's lymphoma presenting at Oncology Department Combined Military Hospital Rawalpindi from August 2009 to July 2010.

METHODS

Thirty patients of diffuse large B-cell non Hodgkin's lymphoma diagnosed on lymph node biopsy presenting for the first time at Oncology Department Combined Military Hospital Rawalpindi were included. They were admitted in the ward and evaluated with history, physical examination and staging investigations. Patients were then planned for first cycle of chemotherapy comprising cyclophosphamide, doxorubicin, and vincristine with prednisolon. After the first cycle of chemotherapy they were monitored for expected neutropenia in the ward. The neutrophil counts were repeated on days 7 and 10 following chemotherapy. Neutropenia was graded as defined in the operational definition and all the data was entered on a specially designed data card.

RESULTS

As much as 3.3% of patients suffered from grade IV neutropenia (absolute neutrophil count of <0.5x10(9)/L), 3.3% had grade III neutropenia (absolute neutrophil count of 0.5x10(9)/L-0.9x10(9)/L), 6.6% had Grade II neutropenia (absolute neutrophil count 1.0x10(9)/L-1.4x10(9)/L and 10% had Grade I neutropenia (absolute neutrophil count 1.5x10(9)/L-1.9x10(9)/L.

CONCLUSION

Overall 23.2% suffered from neutropenia of all grades post 1st cycle of chemotherapy comprising cyclophosphamide, doxorubicin, vincristine with prednisolon in diffuse large B-cell non Hodgkin's lymphoma. Further studies are required to find the risk factors to predict this complication in our population.

摘要

背景

用于恶性疾病的化疗在首个周期可能会导致严重的中性粒细胞减少，这可能迫使调整剂量并提前终止治疗。本描述性横断面研究旨在观察2009年8月至2010年7月在拉瓦尔品第联合军事医院肿瘤科就诊的弥漫性大B细胞非霍奇金淋巴瘤患者在接受包含环磷酰胺、多柔比星、长春新碱和泼尼松龙的首个化疗周期后中性粒细胞减少的发生率和严重程度。

方法

纳入30例经淋巴结活检确诊为弥漫性大B细胞非霍奇金淋巴瘤且首次在拉瓦尔品第联合军事医院肿瘤科就诊的患者。他们被收治入院，通过病史、体格检查和分期检查进行评估。然后患者计划接受包含环磷酰胺、多柔比星、长春新碱和泼尼松龙的首个化疗周期。在首个化疗周期后，在病房对他们进行预期的中性粒细胞减少监测。化疗后第7天和第10天重复检测中性粒细胞计数。中性粒细胞减少按照操作定义进行分级，所有数据录入专门设计的数据卡。

结果

高达3.3%的患者出现IV级中性粒细胞减少（绝对中性粒细胞计数<0.5×10⁹/L），3.3%出现III级中性粒细胞减少（绝对中性粒细胞计数为0.5×10⁹/L - 0.9×10⁹/L），6.6%出现II级中性粒细胞减少（绝对中性粒细胞计数1.0×10⁹/L - 1.4×10⁹/L），10%出现I级中性粒细胞减少（绝对中性粒细胞计数1.5×10⁹/L - 1.9×10⁹/L）。